CRVO

CervoMed Inc. · NASDAQ

Sector Commercial Services
Industry Miscellaneous Commercial Services
Website cervomed.com
Employees(FY) 4
ISIN US15713L1098

Performance

+0.79%

1W

-3.06%

1M

+43.56%

3M

+144.32%

6M

+215.73%

YTD

+322.63%

1Y

Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of CRVO 2024-05-10

Overview:

In analyzing the technical indicators for CRVO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions to guide investme...

See more ...

Recent News & Updates

2024-05-14 21:54
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-14 20:00
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-04-02 19:00
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now(Globenewswire)
2024-04-01 19:00
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now(Globenewswire)
2024-03-31 20:00
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates(Globenewswire)
2024-03-28 04:05
CervoMed to Participate in Upcoming Investor Conferences(Globenewswire)
2024-03-27 20:30
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors(Globenewswire)
2024-03-04 19:00
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD 2024(Globenewswire)
2024-02-20 19:00
CervoMed to Participate in the BIO CEO and Investor Conference(Globenewswire)
2024-02-19 21:22
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board(Yahoo Finance)
2024-02-11 19:00
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies(Globenewswire)
2024-02-06 19:30
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board(Globenewswire)
2024-02-06 18:00
Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now(Globenewswire)
2024-02-05 18:00
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now(Globenewswire)
2024-02-04 19:00
CervoMed to Participate in the Emerging Growth Conference 67(Globenewswire)
2024-01-09 18:00
Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream(Globenewswire)
2024-01-08 18:00
Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now(Globenewswire)
2024-01-04 19:00
CervoMed to Participate in the Emerging Growth Conference 66(Globenewswire)
2023-11-12 18:00
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights(Prnewswire)
2023-10-29 23:21
CRVO: New Data from Phase 2a Trial Presented at CTAD(Yahoo Finance)
2023-10-25 02:50
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies(Prnewswire)
2023-10-23 19:00
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias(Prnewswire)
2023-10-17 19:00
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies(Prnewswire)
2023-10-04 19:00
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference(Prnewswire)
2023-09-17 22:40
CRVO: Publication in Neurology Highlights Correlation Between ptau181 Level and Response to Neflamapimod(Yahoo Finance)
2023-09-04 19:00
CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-20 20:16
CRVO: Initiating Coverage of CervoMed, Inc.; Phase 2b Trial in Dementia with Lewy Bodies Underway(Yahoo Finance)
2023-08-15 04:01
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma(Yahoo Finance)
2023-03-29 19:00
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases(Yahoo Finance)
2022-12-15 17:30
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities(Yahoo Finance)

Page 1 of 4

previousnext